Navigation Links
Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
Date:8/14/2008

CRANBURY, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) announced today the completion of a Phase 2a clinical trial of PL-3994, a novel, long-acting natriuretic peptide receptor A (NPRA) agonist under development for treatment of heart failure (HF). The Phase 2a trial was a randomized, double-blind, placebo-controlled, single ascending dose study in 21 volunteers with controlled hypertension who received the medication or placebo subcutaneously. The purpose of the study was to demonstrate that PL-3994 can be given safely to patients taking antihypertensive medications commonly administered to heart failure and hypertension patients. The evaluations included safety, tolerability, pharmacokinetics and several pharmacodynamic endpoints, including levels of cyclic guanosine monophosphate (cGMP), a natural messenger nucleotide.

Dosing concluded with the successful achievement of the primary endpoint of the study, a pre-specified reduction in systemic blood pressure. No volunteer experienced a serious or severe adverse event. Elevations in plasma cGMP levels were all observed for several hours after single subcutaneous doses. Additional data analysis is ongoing and will be submitted for presentation when the analysis is complete.

"We are excited to confirm that PL-3994 can be given safely to patients who are taking blood pressure medications," stated Dr. Trevor Hallam, Palatin's Executive Vice President for Research and Development. "As we proceed with an additional Phase 2 study later this year, we will focus on the heart failure patients most in need of new therapies."

The previously announced Phase 1 study demonstrated that PL-3994 can be given safely and leads to a dose-related decrease i
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... PA (PRWEB) June 18, 2013 Demanding ... Ball Lenses engineered of synthetic Sapphire and Glass Ball ... sizes from Swiss Jewel Company , of Philadelphia ... by expanding and collimating the light beams without the ... optical clarity and natural durability (9 mohs) make it ...
(Date:6/18/2013)... DuPont welcomes 48 of the nation’s finest ... AgriScience Teachers Ambassador Academy this week (NATAA) at the ... , The NATAA “Ag Academy” is a professional ... project of the National FFA Foundation and ... The highly recommended agriscience teachers, who are participating ...
(Date:6/18/2013)... , June 18, 2013 ... using the company,s  proprietary AMCA Guided Bone Regeneration (GBR) Dental ... implants. A common problem encountered when patients have ... of sufficient bone volume to house the implant. Consequently there ... bone substitute until the natural bone regenerates. The bone substitute ...
(Date:6/18/2013)... 18, 2013  regulated information — Global biopharmaceutical company ... today announced the launch of a new Pledge campaign ... The Pledge empowers the millions of ... make a personal commitment to demand more: greater understanding ... team and additional partial-onset seizure control.  More information is ...
Breaking Biology Technology:Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6
... , , BOTHELL, Wash., ... BLFS), a leading developer, manufacturer, and marketer of biopreservation ... Sigma-Aldrich(R) will distribute the Company,s proprietary HypoThermosol and CryoStor ... distribution agreement. , , (Logo: ...
... , , , ... Sept. 14 Tobira Therapeutics Inc., a clinical stage ... the treatment of life-threatening and life-altering infectious diseases, today ... multiple-dose randomized study of TBR-652 in sixty healthy volunteers. ...
... ATLANTA, Sept. 14 CryoLife, Inc. (NYSE: ... and cardiovascular tissue processing company, announced today that it is scheduled ... the Grand Hyatt New York in New York City. , ... of CryoLife, Inc., will present Monday, September 21 at 2:00 p.m., ...
Cached Biology Technology:BioLife Solutions Announces HypoThermosol(R) and CryoStor(TM) Distribution Agreement With Sigma-Aldrich 2BioLife Solutions Announces HypoThermosol(R) and CryoStor(TM) Distribution Agreement With Sigma-Aldrich 3Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV 2CryoLife to Present at UBS Global Life Sciences Conference 2
(Date:6/17/2013)... virus in patients with severe brain infections in Vietnam. ... is responsible for the symptoms of disease. , The ... of 644 patients with severe brain infections in the ... of the 122 patients with non-infectious brain disorders that ... nervous system are often fatal and patients who do ...
(Date:6/17/2013)... ST. LOUIS -- In research published in Biochemical ... describe a technology that can detect new, previously unknown ... for viruses even when doctors have not identified a ... , In the new approach, scientists use ... discover viruses. , Taking advantage of the complete deciphering ...
(Date:6/17/2013)... a sugar alcohol produced by fungi, bacteria, and algae, ... The sweetener is also used in the medical field ... to flush out excess fluids and used during surgery ... ease the passage of other drugs. , Now Profs. ... Department of Molecular Microbiology and Biotechnology and the Sagol ...
Breaking Biology News(10 mins):New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3Saint Louis University researchers discover a way to detect new viruses 2Saint Louis University researchers discover a way to detect new viruses 3Artificial sweetener a potential treatment for Parkinson's disease 2
... , Dr. Don Walsh, who co-piloted the historic 1960 deep-sea voyage ... Navy in a ceremony on at 10 a.m. April 15 at ... the only living human to have visited the Challenger Deep ... Walsh is best-known for navigating the bathyscaphe (deep submergence vehicle) Trieste ...
... at The Scripps Research Institute have synthesized a new nano-scale scientific ... off as it detects metallic ions in its immediate surroundings. ... of the International Edition of the journal Angewandte Chemie, this molecule ... in the test tube, and it has potential to be developed ...
... with medical formulations to be accepted by the U.S. Food ... that has serious ethical and moral implications. New research in ... Tel Aviv University,s Faculty of Engineering holds a promise that ... experimental trials. Dr. Gefen,s research into fat cells, published ...
Cached Biology News:New nano-tool synthesized at Scripps Research Institute 2A lab rat -- created in the lab 2
Human GATA-2 Affinity Purified Polyclonal Ab...
... microPET R4 is the lowest priced, full ... the world. Despite the microPET R4 ... systems in all performance categories; count rate ... set., microPET is a dedicated small animal ...
...
... StatMatic I provides a convenient and affordable ... work. Used with an eight-port disposable manifold, ... possible with multi-channel pipettes. The eight-port manifold, ... volumes of 100, 200, 250, or 300mL ...
Biology Products: